Stock Price
468.72
Daily Change
3.05 0.65%
Monthly
10.30%
Yearly
37.17%
Q4 Forecast
455.19

EPS Reference Time Actual Consensus Previous
2026-11-03 FY2026Q3 PM 6.45 5.76 5.64
2026-08-04 FY2026Q2 PM 6.29 5.59 6.02
2026-04-30 FY2026Q1 PM 5.15 4.79 4.90
2026-02-03 FY2025Q4 PM 5.29 4.72 5.31
2025-11-04 FY2025Q3 PM 5.64 5.07 5.58



Peers Price Chg Day Year Date
Takeda 6,937.00 11.00 0.16% 58.67% Nov/16
AbbVie 297.68 2.65 0.90% 27.21% Nov/16
Agios Pharmaceuticals 31.59 -0.17 -0.54% -27.63% Nov/13
ALKERMES 47.34 0.31 0.66% 63.02% Nov/16
Amgen 468.72 3.05 0.65% 37.17% Nov/16
Biogen 253.40 2.92 1.17% 51.24% Nov/13
BioMarin Pharmaceutical 57.23 0.53 0.93% 4.57% Nov/13
Bristol-Myers Squibb 63.17 -0.26 -0.41% 35.41% Nov/16
Coherus Biosciences 0.53 -0.01 -2.41% -55.84% Nov/13
Exelixis 69.00 -0.84 -1.20% 65.67% Nov/13

Indexes Price Day Year Date
US Index 500 7477 -84.19 -1.11% 12.07% Nov/16
USND 24753 -383.47 -1.53% 9.00% Nov/16
US Index 30 51991 -356.70 -0.68% 11.59% Nov/16
US Index 100 27460 -484.15 -1.73% 10.72% Nov/16

Amgen traded at $469.95 this Monday November 16th, increasing $4.28 or 0.92 percent since the previous trading session. Looking back, over the last four weeks, Amgen gained 10.59 percent. Over the last 12 months, its price rose by 37.53 percent. Looking ahead, we forecast Amgen to be priced at 455.19 by the end of this quarter and at 425.15 in one year, according to Trading Economics global macro models projections and analysts expectations.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.



News Stream
Amgen Shares Hit 5-week High
Amgen shares increased to 426.77 USD, the highest since September 2026. Over the past 4 weeks, Amgen gained 13.36%, and in the last 12 months, it increased 43.22%.
2026-10-14
Amgen Stock Price Hits 4-week Low
Amgen shares decreased to 407.08 USD, the lowest since August 2026. Over the past 4 weeks, Amgen gained 0.05%, and in the last 12 months, it increased 43.85%.
2026-09-08
Amgen Stock Price Hits 11-week High
Amgen shares increased to 358.73 USD, the highest since April 2026. Over the past 4 weeks, Amgen gained 6.78%, and in the last 12 months, it increased 28.52%.
2026-06-25